Navigation Links
Xceed Molecular Grants Gen-Probe License to Xceed's Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
Date:6/3/2008

WELLESLEY, Mass., June 3 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, has granted Gen-Probe Incorporated (Nasdaq: GPRO) and its affiliates a non-exclusive license to use Xceed's novel Flow-Thru Chip technology. Gen-Probe expects to incorporate the Xceed technology into its next-generation multiplexed molecular-diagnostics products. Gen-Probe is a global leader in the development, manufacture, and marketing of rapid, accurate, and cost-effective nucleic acid testing products for diagnosing human diseases and screening donated human blood.

Under the terms of the agreement, Gen-Probe will pay up-front licensing and milestone fees to Xceed for non-exclusive access to Xceed's Flow-Thru Chip technology in specific fields. Gen-Probe also has the right to obtain co-exclusive rights (with Xceed) in pre-defined sub-fields. In addition to continuing royalty payments, the agreement provides that Xceed will supply Gen-Probe with Xceed's custom TipChips, its Ziplex(R) automated gene-expression system, and other Xceed products. Additional terms were not disclosed.

"The Flow-Thru Chip technology is well suited for diagnostic tests and we are pleased to have a market leader like Gen-Probe recognize its value for inclusion in their multiplexing strategy," said Xceed President and CEO, David Deems. "Multiplex molecular diagnostics is a burgeoning market, and new tools are required as the era of 'personalized medicine' becomes a reality. Simplicity, reproducibility, cost-effectiveness, and minimal interaction time for lab personnel will be key to the routine adoption of molecular diagnostics in the clinical lab. The Flow-Thru Chip and Ziplex System will make this possible."

Gen-Probe's Executive Vice President and Chief Scientist, Dan Kacian, Ph.D., M.D., commented, "There are many promising applications for moderate-density arrays in clinical diagnostics and other applications, and we believe that Xceed's technologies in combination with our own technologies will facilitate our entry into these expanding markets."

Unlike two-dimensional arrays, Xceed's unique 3D Flow-Thru Chip design enables active transport of targets to probes. The chip is made of porous silicon with channels that extend from the upper to the lower surface of the chip. Molecular interactions occur within the three-dimensional matrix of these channels as target solutions pass through. This approach facilitates specific interactions between target molecules and immobilized probes, resulting in hybridization times that are three- to four-times faster than conventional methods.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex(R) System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, and pre-configured arrays. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit http://www.XceedMolecular.com.


'/>"/>
SOURCE Xceed Molecular
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
2. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
3. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
6. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
7. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
8. CrossFire Beilstein Database Exceeds Ten Million Compounds
9. Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
10. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
11. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017  Spherix Incorporated (Nasdaq: SPEX ) ... of technology and monetization of intellectual property, today provided ... Anthony Hayes , Chief Executive Officer of ... to communicate with shareholders about the status of existing ... on other patent assets that fit with our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. announced ... and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. ... career as an academic and industry preclinical drug developer spans more than three ...
(Date:1/21/2017)... ... January 20, 2017 , ... ... resource to the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of ... of clinical and scientific consultants and contractors. This is the latest step in ...
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
Breaking Biology Technology:
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
Breaking Biology News(10 mins):